Proctor & Gamble’s patent application for Risedronate (actonel) voided in opposition proceedings before Israel Patent Office
Israel returned to the Special 301 Report black-list of countries with inadequate IP protection.
The European Union’s antitrust watchdog said Thursday it had launched an ex officio probe of U.S. pharmaceutical giant Cephalon Inc.’s alleged attempt to pay Teva Pharmaceutical Industries Ltd. to keep Modafinil, a generic version of narcolepsy drug Provigil off the market…. Read More ›
Cosopt patent voided, Appeal Court Upholds Teva’s challenge to Merck’s patent in the UK. good news to Glaucoma sufferers
Cubist Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. (TEVA) have resolved their dispute by Cubist agreeing to license its antibiotic Cubicin to Teva . Under the agreement Teva can start selling its generic version in June 2018 if Cubist is granted a six-month… Read More ›
Following attempts by Teva to obtain regulatory approval of a generic form of Actonel (risedronate), used to treat or prevent osteoporosis and to treat Paget’s bone disease, Warner Chilcott Co. LLC and Hoffmann-La Roche Inc. have launched a suit alleging… Read More ›
Israel’s Teva Pharmaceutical Industries has launched a High Court action in London to revoke the European patent for Seroquel, an anti-depressant developed by AstraZeneca. Currently, no further details are available.
Teva Pharmaceuticals filed an Opposition proceeding to Schwartz’ Pharma’s patent number 149567 titled “Stable salts of novel derivatives of 3-3 diphenylpropylamines”. In response, Schwartz cancelled a dependent claim and filed a new dependent claim. During opposition proceedings the applicant is allowed to delete claims… Read More ›
In opposition proceedings number IL 172563, concerning a Merck patent application for “Phosphoric Acid Salt of a Dipeptidal Petidase-IV Inhibitor” Teva requested permission to submit an Opinion by a medical expert concerning experimental evidence conducted under his supervision. The opinion was… Read More ›
Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York has denied Teva’s request for an order directing the generic-drug manufacturers Momenta Pharmaceuticals and Sandoz to provide advance notice of their ability and intention… Read More ›